Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Consumer
Moving
Living
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Consumer
Moving
Living
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Novartis
(NYSE:NVS)
Intraday
$96.00
-1.27
[-1.31%]
After-Hours
$96.00
0
[0.00%]
GET A REPORT ON
NVS
SENT RIGHT TO YOUR INBOX
EMAIL*
Submit
Cancel
Get Report
Watch
Perks
Buy
Compare Brokers
$96.00
-1.27
[-1.31%]
At close: Mar 18
$96.00
0
[0.00%]
After Hours: 7:37PM EDT
GET A REPORT ON
NVS
SENT RIGHT TO YOUR INBOX
EMAIL*
Submit
Cancel
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Novartis Stock (NYSE:NVS)
Novartis Stock (NYSE: NVS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 15, 2024
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
Vandana Singh
-
3 days ago
Monday, March 11, 2024
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Piero Cingari
-
Mar 11, 2024, 10:38AM
Friday, March 08, 2024
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
Vandana Singh
-
Mar 8, 2024, 10:02AM
Beigene Said It Filed Patent Infringement Suits Against Sandoz, MSN Pharmaceuticals
Charles Gross
-
Mar 8, 2024, 6:09AM
Thursday, March 07, 2024
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Vandana Singh
-
Mar 7, 2024, 9:15AM
Wednesday, March 06, 2024
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Vandana Singh
-
Mar 6, 2024, 4:21PM
Tuesday, March 05, 2024
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
Natan Ponieman
-
Mar 5, 2024, 4:45PM
FDA Approves JUBBONTI By SANDOZ INC
Benzinga Newsdesk
-
Mar 5, 2024, 10:26AM
Novartis AG Says Shareholders Approve Dividend Increase To CHF 3.30 (+3.1%) Per Share For 2023; Representing A 3.7% Yield And ~58% Payout Of Free Cash Flow
Benzinga Newsdesk
-
Mar 5, 2024, 9:23AM
Monday, March 04, 2024
Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children
Vandana Singh
-
Mar 4, 2024, 11:34AM
Novartis Presents New Data On Safety And Efficacy Of Zolgensma, One-time Gene Therapy For Spinal Muscular Atrophy, Including Maintained And Improved Motor Milestones In Older And Heavier Atrophy Children
Benzinga Newsdesk
-
Mar 4, 2024, 4:55AM
Wednesday, February 28, 2024
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
Stjepan Kalinic
-
Feb 28, 2024, 2:43PM
Monday, February 26, 2024
Merck Said Along With AstraZeneca, Filed A Patent Infringement Lawsuit In The U.S. District Court For The District Of New Jersey Against Novartis Sandoz Unit
Charles Gross
-
Feb 26, 2024, 4:53PM
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
Vandana Singh
-
Feb 26, 2024, 10:52AM
Friday, February 23, 2024
BMO Capital Initiates Coverage On Novartis with Market Perform Rating, Announces Price Target of $114
Benzinga Newsdesk
-
Feb 23, 2024, 1:38PM
Thursday, February 22, 2024
Looking Into Novartis's Recent Short Interest
Benzinga Insights
-
Feb 22, 2024, 8:15AM
Friday, February 16, 2024
Novartis Announces The FDA Has Approved Xolair As First And Only Medicine For Children And Adults With One Or More Food Allergies
Benzinga Newsdesk
-
Feb 16, 2024, 11:28AM
Wednesday, February 14, 2024
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Vandana Singh
-
Feb 14, 2024, 3:11PM
Erasca Announces Two Clinical Trial Collaboration And Supply Agreements For Trametinib To Evaluate Naporafenib Combination In SEACRAFT-1 And SEACRAFT-2 Trials
Benzinga Newsdesk
-
Feb 14, 2024, 8:10AM
Tuesday, February 06, 2024
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
Vandana Singh
-
Feb 6, 2024, 2:37PM
MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga Newsdesk
-
Feb 6, 2024, 1:49PM
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Vandana Singh
-
Feb 6, 2024, 8:46AM
Monday, February 05, 2024
MorphoSys Enters Into Business Combination Agreement To Be Acquired By Novartis For €2.7 Billion Equity Value; €68/Share In cash
Benzinga Newsdesk
-
Feb 5, 2024, 4:53PM
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Erica Kollmann
-
Feb 5, 2024, 12:31PM
Novartis AG In Advanced Talks To Acquire MorphoSys AG
Benzinga Newsdesk
-
Feb 5, 2024, 10:17AM
Friday, February 02, 2024
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
Vandana Singh
-
Feb 2, 2024, 2:01PM
Thursday, February 01, 2024
Allarity Therapeutics Said on Jan 26 Received Notice From Novartis to Terminate Agreement That Provided Co With the Right to Dovitinib Based on Material Breach for Lack of Financial Payment
Charles Gross
-
Feb 1, 2024, 4:52PM
Wednesday, January 31, 2024
Novartis shares are trading lower after the company reported worse-than-expected Q4 financial results.
Benzinga Newsdesk
-
Jan 31, 2024, 2:24PM
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Jan 31, 2024, 1:18PM
Why Is European Pharma Giant Novartis Stock Trading Lower Today?
Vandana Singh
-
Jan 31, 2024, 8:16AM
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
Shanthi Rexaline
-
Jan 31, 2024, 7:46AM
Alphabet Reports Q4 Results, Joins AMD, Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor
-
Jan 31, 2024, 6:10AM
Earnings Scheduled For January 31, 2024
Benzinga Insights
-
Jan 31, 2024, 6:09AM
Novartis Says Net Sales Is Expected To Grow 5% (At Constant Currency) CAGR 2023-2028 With Core Operating Income Margin Expanding To ~40%+ By 2027
Benzinga Newsdesk
-
Jan 31, 2024, 3:20AM
Novartis Expects 2024 Net Sales To Grow Mid-single Digit And Core Operating Income Is Expected To Grow High Single-Digit
Benzinga Newsdesk
-
Jan 31, 2024, 3:19AM
Novartis Q4 Adjusted EPS $1.53 Misses $1.62 Estimate, Sales $11.42B Miss $11.76B Estimate
Benzinga Newsdesk
-
Jan 31, 2024, 3:17AM
Tuesday, January 30, 2024
Earnings Outlook For Novartis
Benzinga Insights
-
Jan 30, 2024, 12:01PM
Monday, January 29, 2024
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
Shanthi Rexaline
-
Jan 29, 2024, 5:51AM
Friday, January 26, 2024
Lantheus Confirmed The Company And Its Subsidiary Were Sued By Advanced Accelerator Applications, Novartis Unit For Patent Infringement For Abbreviated New Drug Application For Lutetium Lu 177 Dotatate, Generic Version Of Lutathera - 8K
Benzinga Newsdesk
-
Jan 26, 2024, 8:13AM
Wednesday, January 24, 2024
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
Vandana Singh
-
Jan 24, 2024, 10:36AM
Tuesday, January 23, 2024
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
Vandana Singh
-
Jan 23, 2024, 8:19AM
Morgan Stanley Initiates Coverage On Novartis with Equal-Weight Rating, Announces Price Target of $114
Benzinga Newsdesk
-
Jan 23, 2024, 6:49AM
FDA Reported Monday It Is Requiring Boxed Warning For CAR-T Cancer Therapies
Charles Gross
-
Jan 23, 2024, 5:13AM
Monday, January 22, 2024
Coherus Earlier Announced Agreement To Divest Ophthalmology Franchise Cimerli To Novarts' Sandoz Unit For $170M Upfront All Cash Deal
Charles Gross
-
Jan 22, 2024, 5:29AM
Friday, January 19, 2024
Novartis Announced Data From Phase III NETTER-2 Trial Showed Lutathera Plus Long-Acting Release Octreotide Reduced Risk Of Disease Progression Or Death By 72% As First-Line Therapy For Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
Benzinga Newsdesk
-
Jan 19, 2024, 10:06AM
Friday, January 12, 2024
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Vandana Singh
-
Jan 12, 2024, 2:38PM
Thursday, January 11, 2024
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
Vandana Singh
-
Jan 11, 2024, 2:22PM
"Novartis Pursuit Of Cytokinetics Cools; Swiss Drug Maker Had Been Expected To Clinch Deal For Heart-drug Developer As Soon As This Week" - WSJ
Benzinga Newsdesk
-
Jan 11, 2024, 12:22PM
Tuesday, January 09, 2024
What's Been Happening With Cytokinetics Stock?
Ryan Gustafson
-
Jan 9, 2024, 3:42PM
Monday, January 08, 2024
Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today?
Vandana Singh
-
Jan 8, 2024, 2:24PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch